DrJulius Ohrnberger
Honorary Lecturer
School of Public Health - Faculty of Medicine
Orcid identifier0000-0001-7097-4917 (opens in a new tab)
- Honorary LecturerSchool of Public Health - Faculty of Medicine
- 020 7594 0923 (Work)
- 33A, 47 Praed Street, St Mary's Campus, United Kingdom
RESEARCH
Summary
Understanding the economic potential of HIV prevention and treatment interventions (HIVPTI) is key for policy makers to allocate scarce health care resources most efficiently. With HIV a barrier to sustainable development, HIVPTI have potential to improve individual economic productivity by reducing lost healthy days and enabling individuals in their economic productivity. However, there is limited evidence on the economic potential of HIVPTI. My research project focuses on South Africa where about 20 per cent of the global HIV population lives and where consequentially economic potential due to HIVPTI is largest. The research is funded by the MRC Skills Development Fellowship.
My research combines methodologies from infectious disease modelling and health economic impact and cost-effectiveness analysis to understand the long-term effects of HIVPTI on economic development. The aim is to analyse the effect of HIVPTI on individual productivity effects, e.g. sickness absence, days lost to accessing health care and presenteeism, and simulate the long-term economic effects on the individual and on the country-level. The developed analytical approach will also be useful for future studies aiming at understanding the economic potential of prevention and treatment of other infectious diseases in other contexts.
I combine three unique studies for the analysis: The HPTN 071 (PopART) trial, a HIVPTI trial in South Africa and Zambia; The National Income Dynamics Study (NIDS); and the Demographic Health Survey (DHS) South Africa are representative studies of the South African population.
The work is supervised by Dr Katharina Hauck from Imperial College who is the leading health economist on the PopART trial, Prof Christoph Fraser, lead of the Pathogen Dynamics Group at the University of Oxford and Dr Anne Cori, an expert in modelling of infectious diseases at Imperial College.
Prof. Meyer-Rath, a leading epidemiologist on the economics and cost-effectiveness of HIV interventions in South Africa based at WITS University Johannesburg, collaborates with me on the estimation of country wide effects and translation of findings into policy.
Further collaborations include Dr Eleonora Fichera, head of the department of economics at the University of Bath, Dr Laura Anselmi who is an expert in health resource allocation and health systems analysis based at the University of Manchester, and Prof Matt Sutton, lead of HOPE research group at the University of Manchester, in an advisory role.
Understanding the economic potential of HIV prevention and treatment interventions (HIVPTI) is key for policy makers to allocate scarce health care resources most efficiently. With HIV a barrier to sustainable development, HIVPTI have potential to improve individual economic productivity by reducing lost healthy days and enabling individuals in their economic productivity. However, there is limited evidence on the economic potential of HIVPTI. My research project focuses on South Africa where about 20 per cent of the global HIV population lives and where consequentially economic potential due to HIVPTI is largest. The research is funded by the MRC Skills Development Fellowship.
My research combines methodologies from infectious disease modelling and health economic impact and cost-effectiveness analysis to understand the long-term effects of HIVPTI on economic development. The aim is to analyse the effect of HIVPTI on individual productivity effects, e.g. sickness absence, days lost to accessing health care and presenteeism, and simulate the long-term economic effects on the individual and on the country-level. The developed analytical approach will also be useful for future studies aiming at understanding the economic potential of prevention and treatment of other infectious diseases in other contexts.
I combine three unique studies for the analysis: The HPTN 071 (PopART) trial, a HIVPTI trial in South Africa and Zambia; The National Income Dynamics Study (NIDS); and the Demographic Health Survey (DHS) South Africa are representative studies of the South African population.
The work is supervised by Dr Katharina Hauck from Imperial College who is the leading health economist on the PopART trial, Prof Christoph Fraser, lead of the Pathogen Dynamics Group at the University of Oxford and Dr Anne Cori, an expert in modelling of infectious diseases at Imperial College.
Prof. Meyer-Rath, a leading epidemiologist on the economics and cost-effectiveness of HIV interventions in South Africa based at WITS University Johannesburg, collaborates with me on the estimation of country wide effects and translation of findings into policy.
Further collaborations include Dr Eleonora Fichera, head of the department of economics at the University of Bath, Dr Laura Anselmi who is an expert in health resource allocation and health systems analysis based at the University of Manchester, and Prof Matt Sutton, lead of HOPE research group at the University of Manchester, in an advisory role.